Target Researchers SiriusXT’s SXT system is designed for disease research and drug discovery, offering a high-throughput, bench-top soft X-ray tomography solution that can enable faster, in-depth cellular imaging. Sales opportunities exist with academic labs and pharmaceutical R&D teams focusing on disease pathways and protein-drug interactions.

Drug Discovery Enablement The ability to image whole, hydrated cells in 3D at high resolution supports understanding of protein-drug interactions and bio-engineering processes. Position the SXT as a tool to accelerate target validation, mechanism studies, and high-content screening in drug pipelines.

Compact High-Throughput Advantage As the first bench-top SXT system enabling rapid full-cell tomography, SiriusXT can appeal to labs with limited space and the need for scalable throughput. Emphasize ease of integration, maintenance minimal downtime, and potential for multi-site deployment.

Funding and Collaboration With prior recognitions in early-stage and startup programs and a total funding pool, opportunities exist to partner on grant-funded equipment acquisitions, pilot programs, and technology validations within universities and biotech centers.

Strategic Partnerships Identify potential alignment with CROs, contract research labs, and core facilities at large research institutions and biopharma players. Highlight the ability to co-develop use cases, provide training, and offer service/support packages to expand adoption.